Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases, serving patients and healthcare professionals through its own operations and collaborations. Its medicines address eye, allergic and… From the company’s description.
In fiscal 2025, Regeneron Pharmaceuticals reported revenue of $14.34B, up 1.0% from fiscal 2024, and net income of $4.50B. Its operating margin was 24.9%, and operations generated $4.98B in cash. Over the twelve months to Jun 30, 2026, revenue was $15.53B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Regeneron Pharmaceuticals does
In the company’s own words
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases, serving patients and healthcare professionals through its own operations and collaborations. Its medicines address eye, allergic and inflammatory, cancer, cardiovascular and metabolic, neurological, hematologic, infectious, and rare diseases. Key products include EYLEA and EYLEA HD for retinal diseases, Dupixent for allergic and inflammatory conditions, and Libtayo for cancer; other marketed medicines include Praluent, Kevzara, Evkeeza, Ordspono, and Lynozyfic. Regeneron also develops a broad clinical pipeline and uses proprietary antibody, genetic engineering, and genetic medicine platforms, including VelociSuite and the Regeneron Genetics Center, to support drug discovery and development. Its commercial arrangements include collaborations with Sanofi and Bayer, which market certain products globally or outside the United States, while Regeneron retains U.S. commercialization rights for EYLEA. The company reported revenue of $14.3 billion for fiscal 2025. Its website is www.regeneron.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- TARRYTOWN, NY
- Fiscal year end
- December
- CIK
- 872589
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Regeneron Pharmaceuticals — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Regeneron Pharmaceuticals’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Regeneron Pharmaceuticals’s bonds, as funds hold them
Funds report holding 2 issues of Regeneron Pharmaceuticals’s debt, $257.23M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.04%, maturing 2030 to 2050.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Regeneron Pharmaceuticals and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Regeneron Pharmaceuticals's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Regeneron Pharmaceuticals's last four quarterly filings that the numbers alone won't show?”